1. Search Result

Search Result

Targets Recommended: CRISPR/Cas9

Results for "274925-86-9" in MCE Product Catalog:

Cat. No. Product Name Target Research Area
  • HY-106405

    BIA 3-202

    COMT Metabolic Disease
    Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease..